Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population.

Pandya A, Weinstein MC, Gaziano TA.

PLoS One. 2011;6(5):e20416. doi: 10.1371/journal.pone.0020416. Epub 2011 May 31.

2.

Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations.

Gaziano TA, Pandya A, Steyn K, Levitt N, Mollentze W, Joubert G, Walsh CM, Motala AA, Kruger A, Schutte AE, Naidoo DP, Prakaschandra DR, Laubscher R.

BMC Med. 2013 Jul 24;11:170. doi: 10.1186/1741-7015-11-170.

3.

Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.

Pandya A, Weinstein MC, Salomon JA, Cutler D, Gaziano TA.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):25-32. doi: 10.1161/CIRCOUTCOMES.113.000397. Epub 2014 Jan 14.

4.

A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease.

Petersson U, Ostgren CJ, Brudin L, Nilsson PM.

Eur J Cardiovasc Prev Rehabil. 2009 Oct;16(5):536-40. doi: 10.1097/HJR.0b013e32832b1833.

PMID:
19357517
5.

General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB.

Circulation. 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579. Epub 2008 Jan 22.

6.

Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P.

BMJ. 2008 Jun 28;336(7659):1475-82. doi: 10.1136/bmj.39609.449676.25. Epub 2008 Jun 23.

7.

Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart.

Chen L, Tonkin AM, Moon L, Mitchell P, Dobson A, Giles G, Hobbs M, Phillips PJ, Shaw JE, Simmons D, Simons LA, Fitzgerald AP, De Backer G, De Bacquer D.

Eur J Cardiovasc Prev Rehabil. 2009 Oct;16(5):562-70. doi: 10.1097/HJR.0b013e32832cd9cb.

PMID:
19741542
8.

Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.

Metcalf PA, Wells S, Scragg RK, Jackson R.

N Z Med J. 2008 Sep 5;121(1281):49-57.

PMID:
18797484
9.

Screening for cardiovascular risk in asymptomatic patients.

Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS.

J Am Coll Cardiol. 2010 Mar 23;55(12):1169-77. doi: 10.1016/j.jacc.2009.09.066.

10.

Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome.

Onat A, Sari I, Yazici M, Can G, Hergenç G, Avci GS.

Int J Cardiol. 2006 Mar 22;108(1):89-95. Epub 2005 Aug 8.

PMID:
16085325
11.

Comparability of total cardiovascular disease risk estimates using laboratory and non-laboratory based assessments in urban-dwelling South Africans: the CRIBSA study.

Peer N, Lombard C, Steyn K, Gaziano T, Levitt N.

S Afr Med J. 2014 Aug 13;104(10):691-6. doi: 10.7196/samj.8125.

PMID:
25363056
12.

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P.

BMJ. 2007 Jul 21;335(7611):136. Epub 2007 Jul 5.

13.

Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study.

Cui J, Forbes A, Kirby A, Simes J, Tonkin A.

Eur J Cardiovasc Prev Rehabil. 2009 Dec;16(6):660-8. doi: 10.1097/HJR.0b013e32832f3b2b.

PMID:
19738473
14.

Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups.

Brindle P, May M, Gill P, Cappuccio F, D'Agostino R Sr, Fischbacher C, Ebrahim S.

Heart. 2006 Nov;92(11):1595-602. Epub 2006 Jun 8.

15.

Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort.

Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM.

Lancet. 2008 Mar 15;371(9616):923-31. doi: 10.1016/S0140-6736(08)60418-3.

16.

Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative.

Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, Rossouw JE, Wassertheil-Smoller S, Ridker PM.

Circulation. 2012 Apr 10;125(14):1748-56, S1-11. doi: 10.1161/CIRCULATIONAHA.111.075929. Epub 2012 Mar 7.

17.
18.

The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre study.

Steyn K, Levitt NS, Hoffman M, Marais AD, Fourie JM, Lambert EV, Gaziano TA, Kepe L, Lombard CJ.

Ethn Dis. 2004 Spring;14(2):233-42.

PMID:
15132209
19.

Performance of Framingham cardiovascular risk scores by ethnic groups in New Zealand: PREDICT CVD-10.

Riddell T, Wells S, Jackson R, Lee AW, Crengle S, Bramley D, Ameratunga S, Pylypchuk R, Broad J, Marshall R, Kerr A.

N Z Med J. 2010 Feb 19;123(1309):50-61.

PMID:
20186242
20.

Blood glucose may be an alternative to cholesterol in CVD risk prediction charts.

Braun J, Bopp M, Faeh D.

Cardiovasc Diabetol. 2013 Jan 25;12:24. doi: 10.1186/1475-2840-12-24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk